Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 5002

BillFederalSenatePassed Senate
To allow for alternatives to animal testing for purposes of drug and biological product applications.
About This Bill
Passed
Congress
117th (2021–2023)
Introduced
September 29, 2022
Cosponsors (11)
3D 6R
View PDF ↗

Summary

Highlight any text to annotate
FDA Modernization Act 2.0 This bill authorizes the use of certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the Food and Drug Administration to investigate the safety and effectiveness of a drug. The bill also removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.